Myeloma Institute for Research and Therapy
Home
What is Myeloma?
About the Institute
Referring or
Becoming a Patient
Our Doctors and Staff
  Our Doctor Team
  Our Nursing Team and Other Health Professionals
UAMS
News/Events/Press Releases
Scientific Publications/Research
About Little Rock & Arkansas
About UAMS
About The Winthrop P. Rockefeller Cancer Institute
Travel, Hotels, Directions & Maps, UAMS Dining
Other Sources of Myeloma Information
Contact Us
Make a Donation

Job Opportunities

Associated Faculty

Michele Fox, M.D.
fox.jpg (10103 bytes)Professor of Pathology 
Director, Cell Therapy and Transfusion Medicine

M.D., Karolinska Institute, Sweden
Residency (medicine), Georgetown University Hospital, Washington, D.C.
Fellowship (medical oncology, hematology), Georgetown University Hospital 
Senior Staff Fellow, National Institutes of Health, Bethesda, Maryland
Clinical Assistant Professor, Bone Marrow Transplantation, Georgetown University Hospital
Associate Professor, Blood and Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland
Special interests: stem cell biology, transfusion medicine

Selected Publications:

Montgomery M, Cottler-Fox M.  Mobilization and collection of autologous hematopoietic progenitor/stem cells.  Advances in Clinical Hematology and Oncology. 2007; 5(2):127-36.
 
Theus S, Theus J, Cottler-Fox M.   Umbilical cord blood infection with clinical strains of Mycobacterium tuberculosis: a novel model.  Cytotherapy 2007; 9(7):647-53.

Shi J, Tricot G, Szmania S, Rosen N, Garg T, Malaviarachchi P, Moreno A, DuPont B, Hsu K, Baxter-Lowe L, Cottler-Fox M, Shaughnessy J, Jr., Barlogie B, and van Rhee F.  Transfusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec;143(5):641-53.
 
Tricot G, Cottler-Fox M, Hoering A, Szymonifika J, van Rhee F Zangari M, Barlogie B. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.  Haematologica 2008; Nov;93(11):1739-42.

Tricot G, Cottler-Fox M, Badel K, Calandra G.  Safety and efficacy assessment of perixafor in patients with multiple myeloma proven or predicted to be poor mobilizers including assessment of tumor cell mobilzation.  Haematologica 2009, in press.


 

About Multiple Myeloma // About the Myeloma Institute // Becoming a Patient
Highlights of Our Myeloma Program  // Our Physician Team // Our Nursing Team
News/Events/Press Releases // Scientific Publications/Research
About Little Rock & Arkansas // About UAMS // About The Winthrop P. Rockefeller Cancer Institute
Travel/Directions/Maps // Contact Us // Make a Donation

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.

Notice of Privacy Practices
Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences